Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial

P Harter, A Bois, M Hahmann, A Hasenburg… - Annals of surgical …, 2006 - Springer
Background The role of cytoreductive surgery in relapsed ovarian cancer is not clearly
defined. Therefore, patient selection remains arbitrary and depends on the center's …

Adoptive Transfer of Tumor Cytotoxic Macrophages Generated in Vitro from Circulating Blood Monocytes: A New Approach to Cancer Immunotherapy

R Andreesen, C Scheibenbogen, W Brugger, S Krause… - Cancer research, 1990 - AACR
Cells of the macrophage lineage are considered to be of special importance in the defense
of the host against tumor development and spread. Immunotherapeutic strategies to …

A risk model for secondary cytoreductive surgery in recurrent ovarian cancer: an evidence-based proposal for patient selection

WJ Tian, DS Chi, J Sehouli, CG Tropé, R Jiang… - Annals of surgical …, 2012 - Springer
Background To develop a risk model for predicting complete secondary cytoreductive
surgery (SCR) in patients with recurrent ovarian cancer. Methods Individual data of 1075 …

Topotecan weekly versus conventional 5-day schedule in patients with platinum-resistant ovarian cancer: a randomized multicenter phase II trial of the North-Eastern …

J Sehouli, D Stengel, P Harter, C Kurzeder… - Journal of Clinical …, 2011 - ascopubs.org
Purpose Weekly administration of topotecan (Tw) is less toxic and widely considered a
better treatment option than conventional 5-day therapy (Tc) in women with platinum …

Diagnosis of breast cancer with infrared spectroscopy from serum samples

J Backhaus, R Mueller, N Formanski, N Szlama… - Vibrational …, 2010 - Elsevier
The detection of breast cancer has a special value in the diagnosis of cancer diseases. It is
the most frequent type of cancer among women's. We have developed a simple and rapid …

[PDF][PDF] First-line trastuzumab plus epirubicin and cyclophosphamide therapy in patients with human epidermal growth factor receptor 2–positive metastatic breast …

M Untch, M Muscholl, S Tjulandin, W Jonat… - Journal of clinical …, 2010 - researchgate.net
Purpose A high incidence of congestive heart failure (CHF) has been observed in patients
with metastatic breast cancer (MBC) receiving doxorubicin-based chemotherapy and …

Effect of celecoxib vs placebo as adjuvant therapy on disease-free survival among patients with breast cancer: the REACT randomized clinical trial

RC Coombes, H Tovey, L Kilburn, J Mansi… - JAMA …, 2021 - jamanetwork.com
Importance Patients with breast cancer remain at risk of relapse after adjuvant therapy.
Celecoxib has shown antitumor effects in preclinical models of human breast cancer, but …

Course, patterns, and risk-factors for chemotherapy-induced emesis in cisplatin-pretreated patients: a study with ondansetron

A Du Bois, HG Meerpohl, FGM Kommoss… - European journal of …, 1992 - Elsevier
Vomiting and nausea are the most distressing side-effects of cancer chemotherapy. With
standard antiemetic regimens (eg metoclopramide based combinations) sufficient antiemetic …

Phase I study of paclitaxel administered as a 1-hour infusion: toxicity and pharmacokinetics.

H Maier-Lenz, B Hauns, B Haering, J Koetting… - Seminars in …, 1997 - europepmc.org
Paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) is one of the most important
new drugs used in the treatment of solid tumors. Use of paclitaxel, however, is associated …

Studies on the activation of mouse bone marrow‐derived macrophages by the macrophage cytotoxicity factor (MCF)

HG Meerpohl, ML Lohmann‐Matthes… - European journal of …, 1976 - Wiley Online Library
The capacity of bone marrow‐derived macrophages to be rendered cytotoxic by
macrophage cytotoxicity factor (MCF) at different stages of maturation was tested. Under in …